Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Clinical trial NCT04303169 · COMPLETED
Trial details
- NCT number
- NCT04303169
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-26
- Primary completion
- 2025-09-24
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.